KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Finished Goods: 2023-2024

Historic Finished Goods for Aurinia Pharmaceuticals (AUPH) over the last 2 years, with Dec 2024 value amounting to $903,000.

  • Aurinia Pharmaceuticals' Finished Goods was N/A to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year change of. This contributed to the annual value of $903,000 for FY2024, which is 54.89% up from last year.
  • As of FY2024, Aurinia Pharmaceuticals' Finished Goods stood at $903,000, which was up 54.89% from $583,000 recorded in FY2023.
  • In the past 5 years, Aurinia Pharmaceuticals' Finished Goods registered a high of $903,000 during FY2024, and its lowest value of $583,000 during FY2023.
  • Its 2-year average for Finished Goods is $743,000, with a median of $743,000 in 2023.
  • Data for Aurinia Pharmaceuticals' Finished Goods shows a peak YoY spiked of 54.89% (in 2024) over the last 5 years.
  • Over the past 2 years, Aurinia Pharmaceuticals' Finished Goods (Yearly) stood at $583,000 in 2023, then surged by 54.89% to $903,000 in 2024.